HER2-targeted therapy in colorectal cancer: a comprehensive review
Mar 14, 2025 · HER2 overexpression or amplification is identified in 2–4% of metastatic CRCs (mCRC) patients, representing a potential therapeutic target. It is also associated with …
HER2-Positive Metastatic Colorectal Cancer - PubMed
Abstract Targeted treatment strategies are available for human epidermal growth factor receptor 2 (HER2)-positive (amplified and/or overexpressed) metastatic colorectal cancer (mCRC), and …
Tucatinib Approved for HER2-Positive Colorectal Cancer - NCI
Feb 10, 2023 · “So this treatment represents a fairly substantial breakthrough for patients who have HER2-positive disease” that has returned or started growing again. HER2-positive tumors …
Advances and challenges in targeted therapies for HER2-amplified ...
Apr 25, 2025 · The treatment algorithm for HER2-positive mCRC and the sequence of use of the various anti- HER2 agents have yet to be determined, and academic trials are needed to reach a …
Frontline Zanidatamab Plus Chemo ± Bevacizumab Is Safe, Active in HER2 …
Sep 14, 2024 · Key Takeaways Zanidatamab combined with mFOLFOX6-2, with or without bevacizumab, shows high antitumor activity in HER2-positive mCRC, with a cORR of 90.9% and …
Cancer Treatment Reviews
Apr 1, 2024 · Anti-HER2 small molecular inhibitor, antibodies and antibody-drug conjugates have significantly improved the treatment outcome of patients with HER2 amplified mCRC. Anti …
A systematic review to assess the efficacy of HER2-targeted treatment …
166 Background: Recently, there has been a breakthrough in the treatment and disease control of HER-2 positive mCRC using Trastuzumab (TRA) +Tyrosine Kinase inhibitor (TKI) regimens and …
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive …
This treatment is the first US Food and Drug Administration-approved anti-HER2 regimen for metastatic colorectal cancer and is an important new treatment option for chemotherapy …
FDA approves fam-trastuzumab deruxtecan-nxki with pertuzumab …
4 days ago · On December 15, 2025, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) in combination with pertuzumab …
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive …
Tucatinib plus trastuzumab had clinically meaningful anti-tumour activity and favourable tolerability. This treatment is the first US Food and Drug Administration-approved anti-HER2 …
Skip to content